{"nctId":"NCT01478971","briefTitle":"Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","startDateStruct":{"date":"2011-10"},"conditions":["Chronic Kidney Disease","Anemia"],"count":184,"armGroups":[{"label":"peginesatide injection","type":"EXPERIMENTAL","interventionNames":["Drug: Epoetin","Drug: Peginesatide"]}],"interventions":[{"name":"Epoetin","otherNames":[]},{"name":"Peginesatide","otherNames":["Omontys"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have provided written informed consent in accordance with institutional, local, and national guidelines\n* Are ≥18 years of age at the start of screening\n* Have been on in-center hemodialysis for ≥12 weeks at the start of screening\n* Are currently maintained on Epoetin at the start of screening\n* If sexually active and a female of childbearing potential, are willing to use highly effective method of birth control ≥4 weeks before study enrollment and through the study\n* If a female of childbearing potential, have a negative pregnancy test during screening\n\nExclusion Criteria:\n\n* Are scheduled for a renal transplantation during study (Note: patients awaiting transplantation with no date scheduled may enroll.)\n* Have an active malignancy or malignancy treated within one year prior to the start of screening for curative or palliative intent (Note: patients with non-melanoma skin cancers may enroll.)\n* Have known intolerance to any ESA or PEGylated molecule\n* Have been exposed to any investigational agent during the four weeks prior to the start of screening or are anticipated to receive such agents during the study\n* Have any significant medical or psychiatric condition judged by the investigator to prevent informed consent or study compliance\n* Are pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Undergoing Conversion to Peginesatide Injection","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Peginesatide Dosing","description":"The starting dose, mean dose throughout the study, and mean dose during the last week of treatment of peginesatide.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"2.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"3.68"}]}]}]},{"type":"SECONDARY","title":"Peginesatide Dose Deviations","description":"Data collected by sponsor of study (Affymax), and sponsor did not provide aggregate summary data.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With Hemoglobin Levels Greater Than 10 and Less Than or Equal to 11 g/dL","description":"Percentage of participants with hemoglobin values within the hemoglobin range of 10-11 g/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"44.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null},{"groupId":"OG001","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"49.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"44.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Received at Least One Intravenous Iron Dose","description":"Participants received iron supplementation during the study to prevent iron deficiency and to maintain iron stores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"73.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Received a Whole Blood or Red Blood Cell Transfusion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":64,"n":178},"commonTop":["Pain in extremity","Arteriovenous fistula site complication","Fall","Diarrhoea","Vomiting"]}}}